Basket Trials (as of August 2, 2021)

ENGOT-GYN5/NOGGO/IMPROVE

Leading group: NOGGO

Clinical Trial Study:  Expression XI - Improve

Planned number of patients: 1000

Participating groups: 

TBA

Planned start in Q3 2021

 

ENGOT-GYN4/NOGGO/EXPRESSION IX

Leading group: NOGGO

Clinical Trial Study:  Expression IX - Longterm survival with gynecological cancer

Planned number of patients: 1000

Participating groups: 

TBA

 

ENGOT-GYN3/AGO/LIO

Leading group: AGO

Clinical Trial Study:  LIO-1: A Phase 1b/2, Open-Label Study to Evaluate the Safety and Efficacy of Lucitanib in Combination With Nivolumab in Patients With An Advanced, Metastatic Solid Tumor

Planned number of patients: 161

Participating groups: 

BGOG, GEICO, MITO

 

ENGOT-GYN2/GINECO/BOUQUET

Leading group: GINECO

Clinical Trial Study:  A multicenter, multi-arm, open-label, genomics-driven phase II study evaluating the clinical benefit of molecularly targeted therapies alone or in combination in patients with progressive locally-advanced or metastatic rare gynecologic tumors after one line of systemic therapy

Planned number of patients: 20 patients per cohort

Participating groups: 

AGO, GEICO, A-AGO, BGOG, CEEGOG

 

ENGOT-GYN1/NCRI/ATARI

Leading group: NCRI

Clinical Trial Study: ATARI Trial: ATr inhibitor in combination with olaparib in gynaecological cancers with ARId1A loss or no loss  

Planned number of patients: 116

Participating groups: 

GINECO, Princes Margaret Consortium Canada

 

Last ENGOT meeting

ENGOT General Assembly

September 30 - October 1, 2021
Bernstorff Slot
Copenhagen, Denmark

 

You May Also Like

GCA6

GCA WORKSHOPS

Watch the Webcasts 

 

Read More

background

CLINICAL TRIALS

Latest Published Research

 

Read More

patient2

FOR PATIENTS

Key Insights

 

Read More

540x422

ESGO MEETING

ESGO 2021 Congress

Read More